Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MTVA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMetaVia presents Phase 1 data on dual-receptor obesity/liver drug DA-1726 at EASL
Filed May 27, 2026 · Period ending May 27, 2026 · ~1 min read
Key Changes
-
medium
MetaVia disclosed Phase 1 clinical trial results for DA-1726, a dual GLP-1/glucagon receptor drug candidate, at Europe's major liver disease conference (EASL 2026) in a late-breaking poster—suggesting potentially noteworthy early-stage data.
Item 7.01 verify on EDGAR → -
low
The disclosure was furnished under Regulation FD (not formally filed), standard practice for conference presentations and press releases, limiting legal liability while meeting public disclosure requirements.
Item 7.01 verify on EDGAR →
Summary
MetaVia announced Phase 1 data on DA-1726, an experimental drug that activates two metabolic pathways (GLP-1 and glucagon receptors) similar to newer obesity and diabetes treatments. The data was presented as a late-breaking poster at EASL 2026, Europe's premier liver disease conference, which may indicate the results were compelling enough for expedited presentation. DA-1726 is being studied for liver-related conditions, positioning it in the competitive metabolic disease space.
For retail investors, this is an early-stage clinical update—Phase 1 trials test safety and dosing in small groups, not efficacy. The company has not disclosed the actual results in this 8-K, only that data was presented. Watch for follow-up disclosures detailing the Phase 1 outcomes (safety profile, biomarker changes, dose levels tested) and any announcements about advancing to Phase 2 trials, which would signal the drug cleared initial hurdles.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 27, 2026, MetaVia Inc. (the “Company”) issued a press release announcing the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin (OXM) analog agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), in a late-breaking poster presentation at the European Association for the Study of the Liver Congress 2026 (EASL 2026), being held May 27–30 in Barcelona, Spain.
The company disclosed new Phase 1 clinical trial data for its drug candidate DA-1726, which targets two receptor types (GLP1R and GCGR) and is being studied for liver-related conditions. The data was presented at a major European liver disease conference as a late-breaking poster, suggesting the results may be noteworthy enough to warrant expedited presentation.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The information in Item 7.01 of this Report, including Exhibit 99.1 attached hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
This disclosure is being furnished under Regulation FD (fair disclosure) rather than formally filed, which means the company is making the information publicly available to comply with disclosure rules but is not subjecting itself to the same legal liability as a formal SEC filing. This is standard practice for press releases and conference presentations.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify